SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Rein Therapeutics, Inc. (RNTX) (CIK 0001420565) (RNTX) — Jun 26, 2017

Rein Therapeutics, Inc. (RNTX) (CIK 0001420565)
Date: June 26, 2017 · CIK: 0001420565 · Accession: 0001193125-17-213223

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-218474

Date
June 26, 2017
Author
MERRILL LYNCH, PIERCE, FENNER & SMITH
Form
CORRESP
Company
Rein Therapeutics, Inc. (RNTX) (CIK 0001420565)

Letter

Re: Aileron Therapeutics, Inc.

Acceleration Request

June 26, 2017

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Registration Statement on Form S-l (File No. 333-218474)

Ladies and Gentlemen:

As representatives of the several underwriters for the Company’s proposed public offering of up to 4,312,500 shares of common stock, we hereby join the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 4:00 p.m. Eastern time on June 28, 2017, or as soon thereafter as is practicable.

Pursuant to Rule 460 of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Act of 1933, as amended, we wish to advise you that we have effected the following distribution of the Company’s Preliminary Prospectus dated June 19, 2017, through the date hereof:

Preliminary Prospectus dated June 19, 2017:

Approximately 1,300 copies to prospective underwriters, institutional investors, dealers and others

The undersigned advise that they have complied and will continue to comply, and that they have been informed by the participating underwriters and dealers that they have complied with and will continue to comply, with Rule 15c2-8 under the Securities Exchange Act of 1934.

***

Very truly yours,
MERRILL LYNCH, PIERCE, FENNER & SMITH

Show Raw Text
CORRESP
1
filename1.htm

Acceleration Request

 June 26, 2017

Securities and Exchange Commission

 100 F Street, N.E.

Washington, D.C. 20549

Re:
Aileron Therapeutics, Inc.

Registration Statement on Form S-l (File No. 333-218474)

 Ladies and Gentlemen:

As representatives of the several underwriters for the Company’s proposed public offering of up to 4,312,500 shares of common stock, we
hereby join the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 4:00 p.m. Eastern time on June 28, 2017, or as soon thereafter as is practicable.

Pursuant to Rule 460 of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Act of 1933, as
amended, we wish to advise you that we have effected the following distribution of the Company’s Preliminary Prospectus dated June 19, 2017, through the date hereof:

Preliminary Prospectus dated June 19, 2017:

Approximately 1,300 copies to prospective underwriters, institutional investors, dealers and others

The undersigned advise that they have complied and will continue to comply, and that they have been informed by the participating underwriters
and dealers that they have complied with and will continue to comply, with Rule 15c2-8 under the Securities Exchange Act of 1934.

 ***

Very truly yours,

 MERRILL LYNCH, PIERCE, FENNER & SMITH

    INCORPORATED

JEFFERIES LLC

As Representatives of the several Underwriters

 By: MERRILL LYNCH, PIERCE, FENNER & SMITH

          INCORPORATED

By:

/s/ Michele A.H. Allong

Authorized Signatory

By: JEFFERIES LLC

By:

/s/ Michael Judlowe

Authorized Signatory